/ Print /

Cheryl Guttman Krader
Bipolar TURP associated with ‘substantial’ cost savings
Bipolar transurethral resection of the prostate offers an economic benefit compared with monopolar TURP that follows from the clinical differences between the two procedures, concluded investigators who presented their findings at the 2017 Western Section of the AUA annual meeting in Vancouver, BC.
Urethroplasty delay results in more complex repair
Delay to urethroplasty for bulbar urethral strictures is associated with repetitive interventions, stricture lengthening, and more complex repairs that have a greater risk for failure, while scheduling-related delay to reconstruction exposes men to risk for stricture-related complications, according to separate studies presented at the AUA annual meeting in Boston.
Prevent burnout by restoring professional fulfillment
“The answer is to remove the barriers and frustrations that are causing burnout so that physicians can focus on their role as care providers,” advises Paul DeChant, MD, MBA.
Urology-specific APMs to encompass PCa, BPH, OAB
“The APMs being designed by LUGPA allow for participation by all urologists regardless of their practice setting or affiliation,” explains Alec Koo, MD.
How care process models can help your practice
“Care process models… represent a way to decrease variation and waste, and thereby they lead to improved outcomes and significant cost reductions,” says Jay T. Bishoff, MD.
Add-on injectable IOL for pseudophakic AMD maintains near vision
Results from 1 year of follow-up in a multicenter clinical trial show that an add-on (Scharioth Macula Lens [SML], Medicontour) increases near vision without affecting distance vision in pseudophakic patients with age-related macular degeneration (AMD).
Intravitreal brimonidine holds promise for slowing GA growth
Brimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMD
Topline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Role of corticosteroids uncertain in AMD management
There is no doubt that inflammation is a component of age-related macular degeneration (AMD), and yet the role of corticosteroid treatment in the management of eyes with AMD remains uncertain, said Marc de Smet, MD, PhD.
AO imaging offers novel data for understanding retinal disease
Adaptive optics (AO) is providing new insights about retinal structure and may help to identify potential areas for treatment of retinal diseases, said Mina Chung, MD.